Phase II clinical trial of capecitabine and oxaliplatin plus bevacizumab as neoadjuvant treatment for patients with previously untreated unresectable liver-only metastases from colorectal cancer

ABSTRACT: Primary objectives: To evaluate the response rate of patients with previously untreated unresectable liver-only metastases from colorectal cancer treated with neoadjuvant capecitabine and oxaliplatin plus bevacizumab. Primary endpoints: Overall response rate according to RECIST criteria.

DISEASE(S): Metastatic Colorectal Adenocarcinoma With Metastases Involving The Liver Only,Colorectal Cancer Stage Iv

PROVIDER: 2518384 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR